A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS)
-
- STATUS
- Recruiting
-
- participants needed
- 50
Summary
Primary FSGS is a progressive disease that causes the kidneys to scar, to leak protein into the urine and may lead to kidney failure. This study is being done to see whether a new medication, called CXA-10, can reduce the amount of protein in the urine and maintain stable kidney function in patients with primary FSGS. CXA-10 is an investigational medication which means it has not yet been approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary FSGS. The pharmaceutical company sponsoring this study is Complexa, inc.
Description
Details
| Condition | FSGS,Primary Focal Segmental Glomerulosclerosis, |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX6057 |
| Last Modified on | 24 April 2024 |
Eligibility
How to participate?
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.